Marimed (MRMD) Notes Payables (2014 - 2026)

Marimed (MRMD) has 13 years of Notes Payables data on file, last reported at $3.3 million in Q1 2026.

• Notes Payables for Q1 2026 came in at $3.3 million, down 31.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (down 31.15% YoY), and the FY2025 annual result was $2.6 million, down 50.2% from the prior year.
• Notes Payables rose to $3.3 million in Q1 2026 per MRMD's latest filing, from $2.6 million in the prior quarter.
• Over five years, Notes Payables peaked at $5.1 million in Q4 2024 and troughed at $10000.0 in Q1 2022.
• A 5-year average of $2.1 million and a median of $2.3 million in 2025 frame the typical range for Notes Payables.
• The sharpest annual moves came in 2023 and 2024: Notes Payables slumped 80.84% in 2023, then surged 13145.45% in 2024.
• A 5-year view of Notes Payables shows it stood at $3.8 million in 2022, then tumbled by 80.84% to $723000.0 in 2023, then surged by 608.99% to $5.1 million in 2024, then sank by 50.2% to $2.6 million in 2025, then climbed by 29.06% to $3.3 million in 2026.
• Business Quant data shows MRMD's Notes Payables at $3.3 million in Q1 2026, $2.6 million in Q4 2025, and $2.3 million in Q3 2025.